Mucosal Delivery Strategies for Cancer Vaccines

癌症疫苗的粘膜递送策略

• 批准号: 6999933
• 负责人: David Zaharoff
• 金额: $ 4.72万
• 依托单位: NATIONAL CANCER INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-01-01 至 2008-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6999933
• 关键词: antineoplastics; drug delivery systems; laboratory mouse; mucosal immunity; neoplasm /cancer immunology; neoplasm /cancer vaccine; nonhuman therapy evaluation; postdoctoral investigator; secretory immune system

DESCRIPTION (provided by applicant): The goal of this research is to develop novel mucosal vaccination platforms to improve the efficacy of therapeutic cancer vaccines. While recent research has demonstrated limited antitumor responses resulting from standard subcutaneous injections of cancer vaccines, antitumor efficacy may be substantially improved if vaccine delivery is site-specific and/or targeted directly to diseased tissues. Numerous cancers, e.g. lung, colorectal, cervical and Gl cancers arise in tissues served by the common mucosal immune system (CMIS). Activation of a mucosal immune response may lead to a greater effector function against such cancers. Also, since mucosal immunity confers systemic immunity, mucosal vaccination has the potential to reach all cancers. A systematic study and development of mucosal vaccination platforms may enhance the efficacy of therapeutic cancer vaccines. In this study, five platforms will be developed to target mucosal lymphoid tissues via oral, intranasal, intravaginal, intrarectal and intrapulmonary routes. In addition to the salient benefits of immunotherapy, tailored mucosal administrations of vaccines will foster a greater understanding of mucosal immunity potentially impacting prophylaxes of cancers as well as other infections or pathologies.

描述（由申请人提供）：这项研究的目的是开发新型的粘膜疫苗接种平台，以提高治疗性癌症疫苗的功效。虽然最近的研究表明，标准皮下注射癌症疫苗导致的抗肿瘤​​反应有限，但如果疫苗的递送是特定于现场的，并且/或直接靶向患病组织，则抗肿瘤功效可能会大大提高。许多癌症，例如肺，结直肠，宫颈和GL癌在共同粘膜免疫系统（CMIS）提供的组织中出现。 粘膜免疫反应的激活可能会导致对这种癌症的效应功能更大。同样，由于粘膜免疫赋予了系统性免疫，因此粘膜疫苗接种有可能吸引所有癌症。粘膜疫苗接种平台的系统研究和开发可以增强治疗性癌症疫苗的功效。在这项研究中，将开发五个平台通过口服，鼻内，内部，直肠内和肺内途径靶向粘膜淋巴组织。除了免疫疗法的显着益处外，量身定制的疫苗施用还将促进对粘膜免疫的更多了解，从而可能影响癌症的预防以及其他感染或病理。